Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Sarah Sasson is a Post-doctoral Clinical Research Fellow in the Translational Gastroenterology Unit (Nuffield Department of Medicine). She discusses her project and benefits she has drawn from her experience as an Oxford-Celgene Fellow.

Sarah Sasson in black and white picture

What is your research background?

I am an Australian Immunologist and clinical-academic, now working in the Translational Gastroenterology Unit (TGU), Nuffield Department of Medicine, John Radcliffe Hospital.

What are you researching now? 

My project involves characterising the nature of T-cell checkpoint inhibitor-associated colitis. Up to 44% of oncology patients receiving Ipilimumab and Nivolumab develop diarrhoea with 13% having confirmed colitis. We aim to delineate the pathophysiology and risk factors of this entity in the hope of improving patient outcomes and identifying targets for novel therapeutics.

What has your experience of this Fellowship been like?

The Oxford-Celgene Fellowship program has been a remarkable opportunity for me, one for which I’ve moved from Sydney, Australia to pursue. The Fellowship provides funding for cutting edge techniques including single cell genomic analysis. Additionally, the travel allowance facilitates attendance at local and international conferences and to the Celgene headquarters.

What are your aspirations for the future?

One of the things I hope to gain from my time here is the involvement with a broad network of scientists and clinicians, who I can learn from and collaborate with into the future.